Keros Therapeutics (KROS) Cash from Investing Activities (2019 - 2025)
Keros Therapeutics (KROS) reported Cash from Investing Activities of -$134000.0 for Q4 2025, up 53.63% on a YoY basis from -$87220.7 in Q4 2024, and down 1.52% quarter-over-quarter from -$132000.0 in Q3 2025.
Keros Therapeutics (KROS) Cash from Investing Activities (2019 - 2025) Analysis & Trends
Keros Therapeutics has reported Cash from Investing Activities for 7 years, with the latest figure at -$134000.0 in Q4 2025.
- For the quarter ending Q4 2025, Cash from Investing Activities rose 53.63% year-over-year to -$134000.0; the trailing twelve-month figure through Dec 2025 stood at -$1.6 million (up 19.68% YoY), and the FY2025 full-year result was -$1.6 million, up 19.68% from the prior year.
- Cash from Investing Activities for Q4 2025 stood at -$134000.0, down from -$132000.0 in the prior quarter.
- The five-year high for Cash from Investing Activities was -$132000.0 in Q3 2025, with the low at -$1.1 million in Q1 2023.
- Historically, Cash from Investing Activities has averaged -$410550.0 across 5 years, with a median of -$331000.0 in 2022.
- Annual changes were most pronounced in 2021 — Cash from Investing Activities plunged 1721.43% — and 2025, when it surged 65.8%.
- Keros Therapeutics' Cash from Investing Activities stood at -$159000.0 in 2021, then plunged by 120.75% to -$351000.0 in 2022, then slumped by 54.13% to -$541000.0 in 2023, then surged by 46.58% to -$289000.0 in 2024, then soared by 53.63% to -$134000.0 in 2025.
- The last three Cash from Investing Activities figures came in at -$134000.0 (Q4 2025), -$132000.0 (Q3 2025), and -$720000.0 (Q2 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Cash from Investing Activities (Qtr) |
|---|---|---|---|---|---|
| 1 | Alterity Therapeutics | 925,601.88 Bn | 925,601.85 Bn | - | - |
| 2 | Belite Bio | 58,560.00 Bn | 58,560.00 Bn | - | - |
| 3 | Quantum Biopharma | 17,284.41 Bn | 17,284.40 Bn | - | -2.89 Mn |
| 4 | Legend Biotech | 2,809.00 Bn | 2,808.71 Bn | 242.10 Mn | 638.50 Mn |
| 5 | Evaxion A | 1,334.43 Bn | 1,334.42 Bn | - | - |
| 6 | Akari Therapeutics | 1,312.27 Bn | 1,312.26 Bn | - | - |
| 7 | Psyence Biomedical | 212.16 Bn | 212.16 Bn | - | - |
| 8 | Vertex Pharmaceuticals | 114.83 Bn | 107.58 Bn | 2.59 Bn | -431.90 Mn |
| 9 | Abivax | 91.96 Bn | 91.96 Bn | - | 579,519.10 |
| 10 | Keros Therapeutics | 399.01 Mn | 111.61 Mn | - | -134,000.00 |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2025 | -134,000.00 |
| Dec 31, 2025 | -134,000.00 |
| Sep 30, 2025 | -132,000.00 |
| Sep 30, 2025 | -132,000.00 |
| Jun 30, 2025 | -720,000.00 |
| Jun 30, 2025 | -720,000.00 |
| Mar 31, 2025 | -565,000.00 |
| Mar 31, 2025 | -565,000.00 |
| Dec 31, 2024 | -289,000.00 |
| Dec 31, 2024 | -289,000.00 |
| Sep 30, 2024 | -386,000.00 |
| Sep 30, 2024 | -386,000.00 |
| Jun 30, 2024 | -310,000.00 |
| Jun 30, 2024 | -310,000.00 |
| Mar 31, 2024 | -946,000.00 |
| Mar 31, 2024 | -946,000.00 |
| Dec 31, 2023 | -541,000.00 |
| Dec 31, 2023 | -541,000.00 |
| Sep 30, 2023 | -550,000.00 |
| Sep 30, 2023 | -550,000.00 |